Secreted phospholipase A2 as a new enzymatic trigger mechanism for localised liposomal drug release and absorption in diseased tissue

被引:123
作者
Davidsen, J
Jorgensen, K
Andresen, TL
Mouritsen, OG
机构
[1] Tech Univ Denmark, Dept Chem, LiPlasome Pharma AS, DK-2800 Lyngby, Denmark
[2] Royal Danish Sch Pharm, Dept Pharmaceut, DK-2100 Copenhagen, Denmark
[3] Univ So Denmark, Ctr Biomembrane Phys, MEMPHYS, Dept Phys, DK-5230 Odense M, Denmark
来源
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES | 2003年 / 1609卷 / 01期
基金
英国医学研究理事会;
关键词
drug delivery; liposome; phospholipase A(2); permeability; membrane; surfactant; enhancer; lyso-phospholipid; fatty acid;
D O I
10.1016/S0005-2736(02)00659-4
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Polymer-coated liposomes can act as versatile drug-delivery systems due to long vascular circulation time and passive targeting by leaky blood vessels in diseased tissue. We present an experimental model system illustrating a new principle for improved and programmable drug-delivery, which takes advantage of an elevated activity of secretory phospholipase A(2) (PLA(2)) at the diseased target tissue. The secretory PLA2 hydrolyses a lipid-based proenhancer in the carrier liposome, producing lyso-phospholipids and free fatty acids, which are shown in a synergistic way to lead to enhanced liposome destabilization and drug release at the same time as the permeability of the target membrane is enhanced. Moreover, the proposed system can be made thermosensitive and offers a rational way for developing smart liposome-based drug delivery systems. This can be achieved by incorporating specific lipid-based proenhancers or prodestabilisers into the liposome carrier, which automatically becomes activated by PLA2 only at the diseased target sites, such as inflamed or cancerous tissue. (C) 2002 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:95 / 101
页数:7
相关论文
共 40 条
  • [1] Abe T, 1997, INT J CANCER, V74, P245, DOI 10.1002/(SICI)1097-0215(19970620)74:3<245::AID-IJC2>3.0.CO
  • [2] 2-Z
  • [3] Liposomal drug formulations - Rationale for development and what we can expect for the future
    Allen, TM
    [J]. DRUGS, 1998, 56 (05) : 747 - 756
  • [4] Enhancement of the phase transition permeability of DPPC liposomes by incorporation of MPPC: A new temperature-sensitive liposome for use with mild hyperthermia
    Anyarambhatla, GR
    Needham, D
    [J]. JOURNAL OF LIPOSOME RESEARCH, 1999, 9 (04) : 491 - 506
  • [5] BAKKERWOUDENBER.IA, 1995, STEALTH LIPOSOMES, P197
  • [6] CONTINUOUS, VESICLE-BASED FLUOROMETRIC ASSAYS OF 14- AND 85-KDA PHOSPHOLIPASES A(2)
    BAYBURT, T
    YU, BZ
    STREET, I
    GHOMASHCHI, F
    LALIBERTE, F
    PERRIER, H
    WANG, ZY
    HOMAN, R
    JAIN, MK
    GELB, MH
    [J]. ANALYTICAL BIOCHEMISTRY, 1995, 232 (01) : 7 - 23
  • [7] LIPOSOMES FOR THE SUSTAINED DRUG RELEASE INVIVO
    BLUME, G
    CEVC, G
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA, 1990, 1029 (01) : 91 - 97
  • [8] Changes in vesicle morphology induced by lateral phase separation modulate phospholipase A(2) activity
    Burack, WR
    Dibble, ARG
    Allietta, MM
    Biltonen, RL
    [J]. BIOCHEMISTRY, 1997, 36 (34) : 10551 - 10557
  • [9] PURIFICATION AND CHARACTERIZATION OF EXTRACELLULAR PHOSPHOLIPASE-A2 FROM PERITONEAL-CAVITY OF CASEINATE-TREATED RAT
    CHANG, HW
    KUDO, I
    TOMITA, M
    INOUE, K
    [J]. JOURNAL OF BIOCHEMISTRY, 1987, 102 (01) : 147 - 154
  • [10] Modulation of the activities of enzymes of membrane lipid metabolism by non-bilayer-forming lipids
    Cornell, RB
    Arnold, RS
    [J]. CHEMISTRY AND PHYSICS OF LIPIDS, 1996, 81 (02) : 215 - 227